Unicycive Therapeutics (UNCY) EBITDA (2020 - 2026)
Unicycive Therapeutics (UNCY) EBITDA from Mar 31, 2020 to Mar 31, 2026. The TTM Unicycive Therapeutics (UNCY) EBITDA is -$30M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Unicycive Therapeutics (UNCY) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -3.08% |
| 3 Years TTM | +17.84% |
| 5 Years TTM | +66.63% |
| All Time TTM | +66.64% |
Annual EBITDA change of Unicycive Therapeutics (UNCY)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$8.43M | -71.40% |
| 2025 | -$29M | -8.13% |
| 2024 | -$32M | +54.58% |
| 2023 | -$21M | +17.82% |
| 2022 | -$18M | +107.05% |
| 2021 | -$8.51M | +334.18% |
| 2020 | -$1.96M | N/A |
Comparison Unicycive Therapeutics (UNCY) five years EBITDA CAGR with competitors
Unicycive Therapeutics (UNCY) five years EBITDA CAGR is 66.70%.